Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

June 30, 2022

Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

Additional Formats

PDF Version

June 29, 2022

Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer

Additional Formats

PDF Version

May 17, 2022

Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy

Additional Formats

PDF Version

May 5, 2022

Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress

Additional Formats

PDF Version

May 2, 2022

Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

Additional Formats

PDF Version

April 20, 2022

Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine

Additional Formats

PDF Version

April 8, 2022

Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells

Additional Formats

PDF Version

March 10, 2022

Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

Additional Formats

PDF Version

February 18, 2022

Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances

Additional Formats

PDF Version

January 6, 2022

Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Additional Formats

PDF Version

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2022 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter